Get the Stockscreener App
2.20
43.79%
0.67
Pre-market:
2.10
-0.10
-4.55%
Nrx Pharmaceuticals Inc stock is traded at $2.20, with a volume of 12.60M.
It is up +43.79% in the last 24 hours and up +67.94% over the past month.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
See More
Previous Close:
$1.53
Open:
$1.55
24h Volume:
12.60M
Relative Volume:
28.46
Market Cap:
$26.61M
Revenue:
-
Net Income/Loss:
$-30.15M
P/E Ratio:
-3.8596
EPS:
-0.57
Net Cash Flow:
$-21.66M
1W Performance:
+40.13%
1M Performance:
+67.94%
6M Performance:
-9.84%
1Y Performance:
-52.17%
1-Day Range:
$1.47
$2.58
1-Week Range:
$1.41
$2.58
52-Week Range:
$1.10
$7.333
Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile
Name
Nrx Pharmaceuticals Inc
Sector
Industry
Phone
484-254-6134
Address
1201 ORANGE STREET, WILMINGTON
Compare NRXP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRXP
Nrx Pharmaceuticals Inc
|
2.20 | 26.61M | 0 | -30.15M | -21.66M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
402.70 | 103.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
712.33 | 78.28B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
615.00 | 36.77B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.31 | 30.35B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.95 | 27.32B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nrx Pharmaceuticals Inc Stock (NRXP) Latest News
Crowdstrike Holdings Inc (CRWD-Q) QuotePress Release - The Globe and Mail
New Drug Application to the FDA for the Treatment of Suicidal - openPR
NRx Pharmaceuticals Takes Bold Step Toward FDA Approval for NRX-100 in Treatment of Suicidal Depression - Tandav Media
Best Momentum Stocks to Buy for December 30th - Yahoo Finance
NRx Pharmaceuticals seeks FDA nod for suicidal depression drug - Investing.com India
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression - StreetInsider.com
NRx Pharma Advances FDA Application for Groundbreaking Ketamine Depression Treatment - StockTitan
New Strong Buy Stocks for December 24th - MSN
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter and Year to Date 2024 Financial Results on November 14, 2024 - The Eastern Progress Online
NRX Pharmaceuticals chairman Jonathan Javitt buys $46,800 in stock By Investing.com - Investing.com Canada
NRX Pharmaceuticals chairman Jonathan Javitt buys $46,800 in stock - Investing.com India
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire a Premier West Coast Interventional Psychiatric Clinic - Kilgore News Herald
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire its First Florida Interventional Psychiatry Clinics - The Eastern Progress Online
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Conference Call to Discuss Third Quarter and Year to Date 2024 Financial Results to November 18, 2024 - The Eastern Progress Online
Caterpillar Inc (CAT-N) QuotePress Release - The Globe and Mail
NRx Pharmaceuticals (NASDAQ: NRXP) Announces Participation in the NobleCon20Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference December 3-4, 2024 - The Eastern Progress Online
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Publication of Paper Entitled "Quality Assurance of Depression Ratings in Psychiatric Clinical Trials" - The Eastern Progress Online
Ascendiant Capital Markets Issues Positive Forecast for NRx Pharmaceuticals (NASDAQ:NRXP) Stock Price - Defense World
NRx Pharmaceuticals (Nasdaq: NRXP) to Present Keynote Address on - GuruFocus.com
NRx Pharmaceuticals (NRXP) Upgraded to Buy: Here's Why - MSN
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter - GuruFocus.com
NRx Pharmaceuticals CEO to Present at NobleCon20 Emerging Growth Conference - StockTitan
NRx Pharmaceuticals reiterates shares target with Buy rating on Q3 report - Investing.com Nigeria
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Publication of Paper - GuruFocus.com
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Receipt of Po - GuruFocus.com
Earnings call: NRx Pharmaceuticals projects profitability by 2025 - Investing.com Canada
NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Michael Abrams as Chief Financial Officer - The Malaysian Reserve
NRX Pharmaceuticals Strengthens Leadership with New CFO Appointment - TipRanks
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q3 2024 Earnings Call Transcript - Insider Monkey
NRx Pharmaceuticals Reports Progress in Drug Development - TipRanks
NRx Pharmaceuticals names Michael Abrams as new CFO - Investing.com
NRx Pharmaceuticals, Inc. Announces Chief Financial Officer Changes - Marketscreener.com
NRXPNRX Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
NRX Pharmaceuticals Inc (NRXP) Quarterly 10-Q Report - Quartzy
NRX Pharmaceuticals Advances in Mental Health Sector - TipRanks
NRx Pharmaceuticals (NASDAQ:NRXP) Reports Third Quarter and Year to Date 2024 Financial Results and Provides Business Update - PR Newswire
NRx Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
NRx Pharmaceuticals delays Q3 results call to November 18 By Investing.com - Investing.com Canada
NRx Pharmaceuticals delays Q3 results call to November 18 - Investing.com
NRx Pharmaceuticals Reschedules Conference Call To Discuss Third Quarter And Year To Date 2024 Financial Results To November 18, 2024 - XM
NRx Pharmaceuticals (NRXP) Scheduled to Post Earnings on Thursday - Defense World
NRx Pharmaceuticals Sets Q3 2024 Earnings Call for November 14 | NRXP Stock News - StockTitan
McDonald's Corp (MCD-N) QuotePress Release - The Globe and Mail
Nrx Pharmaceuticals Inc Stock (NRXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.48%
1.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):